Nice

Views & Analysis

How to balance the patient voice atop the shifting plates of...

The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm?

News

UCB's bimekizumab 'pre-approved' using NICE fast-track schem...

UCB's bimekizumab hasn't been approved for marketing in Europe yet, but has already been given the nod for NHS use in England and Wales under a new fast-track scheme introduced by NICE.

News

NICE changes its mind on rare bile duct cancer drug from Inc...

Incyte's Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for money.

News

NICE's second Zytiga rejection 'shows need for flexible pric...

NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson's Zytiga as a treatment for men with newly diagnosed advanced prostate cancer, drawing criticism fr

Views & Analysis

NICE feedback?

The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

NICE rejects Orchard's gene therapy for rare childhood disea...

Orchard Therapeutics' gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance.

How to balance the patient voice atop the shifting plates of...

UCB's bimekizumab 'pre-approved' using NICE fast-track schem...

NICE changes its mind on rare bile duct cancer drug from Inc...

NICE's second Zytiga rejection 'shows need for flexible pric...

NICE feedback?

NICE rejects Orchard's gene therapy for rare childhood disea...

Chai raises $130m for AI drug discovery platform

The AI imperative: Establishing the standard for modern clin...

Nice

Editor's Picks